A generic sample preparation method for the multiplex analysis of seven therapeutic monoclonal antibodies in human plasma or serum with liquid chromatography-tandem mass spectrometry

A generic sample preparation method for the multiplex analysis of seven therapeutic monoclonal antibodies in human plasma or serum with liquid chromatography-tandem mass spectrometry
Because of the rising variety of therapeutic monoclonal antibodies (mAbs) used within the clinic, there’s an rising want for sturdy analytical strategies to quantify complete mAb concentrations in human plasma for medical research and therapeutic drug monitoring.
We developed a simple, fast, and sturdy pattern preparation methodology for liquid chromatography-tandem mass spectrometry (LC-MS/MS) evaluation. The tactic was validated for infliximab (IFX), rituximab (RTX), cetuximab (CTX), dupilumab (DPL), dinutuximab (DNX), vedolizumab (VDZ), and emicizumab (EMZ). Saturated ammonium sulfate (AS) was used to precipitate immunoglobulins in human plasma.
After centrifugation, supernatant containing albumin was decanted, and the precipitated immunoglobulin fraction was re-dissolved in buffer containing 6M guanidine. This fraction was then utterly denatured, lowered, alkylated, and trypsin digested. Lastly, signature peptides from the seven mAbs had been concurrently quantified on LC-MS/MS along with their inside requirements secure isotopically labeled peptide counterparts.
The linear dynamic ranges (1 – 512 mg/L) of IFX, CTX, RTX, and EMZ confirmed wonderful (R2 > 0.999) linearity and people of DPL, DNX, and VDZ confirmed good (R2 > 0.995) linearity. The tactic was validated in accordance with the EMA tips. EDTA plasma, sodium citrate plasma, heparin plasma, and serum yielded comparable outcomes.
Ready samples had been secure at room temperature (20°C) and at 5°C for three days, and confirmed no decline in focus for all examined mAbs. This described methodology, which has the benefit of a simple, fast, and sturdy pre-analytical pattern preparation, can be utilized as a template to quantify different mAbs in human plasma or serum.

Reactions and COVID-19 illness development following SARS-CoV-2 monoclonal antibody infusion

SARS-CoV-2 monoclonal antibodies (mAbs) have been proposed as a remedy for gentle to average COVID-19, with favorable outcomes reported in medical trials and an emergency use authorization granted by the Meals and Drug Administration. Actual-world knowledge stay restricted, nevertheless, and thus this evaluation presents findings from over 6,500 outpatient administrations of mAb at services affiliated with a big healthcare group in the US.
Inside 48 hours of mAb infusion, 15.6% (1,043) of sufferers obtained a drug that was indicative of a potential response to the infusion; the vast majority of these had been gentle (e.g., acetaminophen). Roughly 5.2% of sufferers who obtained mAb (n=347) had a post-infusion emergency division go to or admission for COVID-19 illness development.
The outcomes of this evaluation point out that sufferers who obtain mAb have a low chance of each an instantaneous detrimental response to the remedy in addition to future inpatient admission associated to COVID-19 illness development.

A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable web site

Potent neutralizing SARS-CoV-2 antibodies typically goal the spike protein receptor-binding web site (RBS), however the variability of RBS epitopes hampers broad neutralization of a number of sarbecoviruses and drifted viruses. Right here, utilizing humanized mice, we recognized an RBS antibody with a germline VH gene that potently neutralized SARS-related coronaviruses, together with SARS-CoV and SARS-CoV-2 variants.
X-ray crystallography revealed coordinated recognition by the heavy chain of non-RBS conserved websites and the sunshine chain of RBS with a binding angle mimicking the angiotensin-converting enzyme 2 (ACE2) receptor. The minimal footprints within the hypervariable area of RBS contributed to the breadth of neutralization, which was enhanced by immunoglobulin G3 (IgG3) class switching.
The coordinated binding resulted in broad neutralization of SARS-CoV and rising SARS-CoV-2 variants of concern. Low-dose therapeutic antibody remedy in hamsters lowered the virus titers and morbidity throughout SARS-CoV-2 problem. The structural foundation for broad neutralizing exercise could inform the design of a broad spectrum of therapeutics and vaccines.

Pharmacodynamic measures inside tumors expose differential exercise of PD(L)-1 antibody therapeutics

Macromolecules reminiscent of monoclonal antibodies (mAbs) are prone to expertise poor tumor penetration due to their massive dimension, and thus low drug publicity of goal cells inside a tumor might contribute to suboptimal responses. Given the problem of insufficient quantitative instruments to evaluate mAb exercise inside tumors, we hypothesized that measurement of accessible goal ranges in tumors might elucidate the pharmacologic exercise of a mAb and might be used to match the exercise of various mAbs.
Utilizing positron emission tomography (PET), we measured the pharmacodynamics of immune checkpoint protein programmed-death ligand 1 (PD-L1) to guage pharmacologic results of mAbs concentrating on PD-L1 and its receptor programmed cell demise protein 1 (PD-1). For PD-L1 quantification, we first developed a small peptide-based fluorine-18-labeled PET imaging agent, [18F]DK222, which supplied high-contrast pictures in preclinical fashions.
We then quantified accessible PD-L1 ranges within the tumor mattress throughout remedy with anti-PD-1 and anti-PD-L1 mAbs. Making use of mixed-effects fashions to those knowledge, we discovered delicate variations within the pharmacodynamic results of two anti-PD-1 mAbs (nivolumab and pembrolizumab).
In distinction, we noticed starkly divergent goal engagement with anti-PD-L1 mAbs (atezolizumab, avelumab, and durvalumab) that had been administered at equal doses, correlating with differential results on tumor development. Thus, we present that measuring PD-L1 pharmacodynamics informs mechanistic understanding of therapeutic mAbs concentrating on PD-L1 and PD-1.
These findings exhibit the worth of quantifying goal pharmacodynamics to elucidate the pharmacologic exercise of mAbs, unbiased of mAb biophysical properties and inclusive of all physiological variables, that are extremely heterogeneous inside and throughout tumors and sufferers.

Ehrlichia chaffeensis and E. canis hypothetical protein immunoanalysis reveals small secreted immunodominant proteins and conformation-dependent antibody epitopes

Immunomolecular characterization of Ehrlichia chaffeensis (E. ch.) and E. canis (E. ca.) has outlined protein orthologs, together with tandem repeat proteins (TRPs) which have immunodominant linear antibody epitopes. On this examine, we mixed bioinformatic evaluation and cell-free protein expression to determine undiscovered immunoreactive E. ch. and E. ca. hypothetical proteins.
Antigenicity of the E. ch. and E. ca. ORFeomes (n = 1105 and n = 925, respectively) was analyzed by the sequence-based prediction mannequin ANTIGENpro, and we recognized ~250 ORFs in every respective ORFeome as extremely antigenic. The hypothetical proteins (E. ch. n = 93 and E. ca. n = 98) current within the prime 250 antigenic ORFs had been additional investigated on this examine. By ELISA, 46 E. ch. and 30 E. ca.
IVTT-expressed hypothetical proteins reacted with antibodies in sera from naturally E. ch.-infected sufferers or E. ca.-infected canine. Furthermore, 15 E. ch. and 16 E. ca. proteins persistently reacted with a panel of sera from sufferers or canine, together with many that exposed the immunoreactivity of “gold commonplace” TRPs. Antibody epitopes in most (>70%) of those proteins exhibited partial or full conformation-dependence.

Cytokeratin 7 (Cytokeratin 7) Antibody

abx232217-100ug 100 ug
EUR 610.8

Cytokeratin 7 (Cytokeratin 7) Antibody

abx232218-100ug 100 ug
EUR 661.2

Cytokeratin 8 (Cytokeratin 8) Antibody

abx232221-100ug 100 ug
EUR 577.2

Cytokeratin 8 (Cytokeratin 8) Antibody

abx232222-100ug 100 ug
EUR 661.2

Cytokeratin 8 (Cytokeratin 8) Antibody

abx232223-100ug 100 ug
EUR 661.2

Cytokeratin 15 (Cytokeratin 15) Antibody

20-abx225265
  • EUR 444.00
  • EUR 727.20
  • EUR 376.80
  • 100 ul
  • 200 ul
  • 50 ul

Cytokeratin 8 (Cytokeratin 8) Antibody

abx139677-01mg 0.1 mg
EUR 427.2

Cytokeratin 8 (Cytokeratin 8) Antibody

abx139678-01mg 0.1 mg
EUR 427.2

Cytokeratin 8 (Cytokeratin 8) Antibody

20-abx134066
  • EUR 427.20
  • EUR 644.40
  • EUR 260.40
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 14 (Cytokeratin 14) Antibody

20-abx121588
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 4 (Cytokeratin 4) Antibody

20-abx121076
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 8 (Cytokeratin 8) Antibody

20-abx007491
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 8 (Cytokeratin 8) Antibody

20-abx007492
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 14 (Cytokeratin 14) Antibody

20-abx009056
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 8 (Cytokeratin 8) Antibody

20-abx009059
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 7 (Cytokeratin 7) Antibody

20-abx009060
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Cytokeratin 8 (Cytokeratin 8) Antibody

abx010621-100ul 100 ul
EUR 493.2

Cytokeratin 8 (Cytokeratin 8) Antibody (FITC)

abx139679-01mg 0.1 mg
EUR 510

Cytokeratin 8

E8ER1706-92 100ul
EUR 275
Description: Available in various conjugation types.

Cytokeratin 8

E8ER1802-43 100ul
EUR 275
Description: Available in various conjugation types.

Cytokeratin 19

E8ER1803-79 100ul
EUR 275
Description: Available in various conjugation types.

Cytokeratin 8

E8ER1803-87 100ul
EUR 275
Description: Available in various conjugation types.

Cytokeratin 7

E8ER1803-89 100ul
EUR 275
Description: Available in various conjugation types.

Cytokeratin 17

E8ER1803-94 100ul
EUR 275
Description: Available in various conjugation types.

Cytokeratin 17

E8ER1901-01 100ul
EUR 275
Description: Available in various conjugation types.

Cytokeratin 5

E8ER1901-03 100ul
EUR 275
Description: Available in various conjugation types.

Cytokeratin 14

E8ER1901-08 100ul
EUR 275
Description: Available in various conjugation types.

Cytokeratin 7

E8ER1907-15 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 19

E8ET1601-6 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 20

E8ET1601-8 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 17

E8ET1602-16 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 18

E8ET1603-8 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 5

E8ET1605-17 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 8

E8ET1608-32 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 15

E8ET1609-54 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 7

E8ET1609-62 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 10

E8ET1609-75 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 16

E8ET1610-17 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 14

E8ET1610-42 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 5

E8ET1610-43 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 1

E8ET1611-46 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 13

E8ET1611-55 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 6

E8ET1611-70 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 4

E8ET1611-71 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 4

E8ET1611-91 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 9

E8ET1612-77 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 2e

E8ET1701-13 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 17

E8M0407-13 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 8

E8M1603-2 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 7

E8R1309-4 100ul
EUR 275
Description: Available in various conjugation types.

Cytokeratin 13

E8R1601-8 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 5

E8RE6027 100ul
EUR 275
Description: Available in various conjugation types.

CytokeRatin 8

E8RE6073 100ul
EUR 275
Description: Available in various conjugation types.

Cytokeratin 7

MC-901 RN7 Ask for price

Pan Cytokeratin

E8ER1914-74 100ul
EUR 275
Description: Available in various conjugation types.

Cytokeratin antibody

10R-6655 100 ug
EUR 625.2
Description: Mouse monoclonal Cytokeratin antibody

Cytokeratin antibody

10R-6656 100 ug
EUR 625.2
Description: Mouse monoclonal Cytokeratin antibody

Cytokeratin antibody

20R-CP006 100 uL
EUR 550.8
Description: Guinea Pig polyclonal Cytokeratin antibody

Cytokeratin-18 Antibody

F50352-0.08ML 0.08 ml
EUR 140.25
Description: KRT18 is the type I intermediate filament chain keratin 18. Keratin 18, together with its filament partner keratin 8, are perhaps the most commonly found members of the intermediate filament family. They are expressed in single layer epithelial tissues of the body. Mutations in its gene have been linked to cryptogenic cirrhosis.

Cytokeratin-18 Antibody

F50352-0.4ML 0.4 ml
EUR 322.15
Description: KRT18 is the type I intermediate filament chain keratin 18. Keratin 18, together with its filament partner keratin 8, are perhaps the most commonly found members of the intermediate filament family. They are expressed in single layer epithelial tissues of the body. Mutations in its gene have been linked to cryptogenic cirrhosis.

CK18 (Cytokeratin 18)

MO47021 100 ul
EUR 418.8

CK19 (Cytokeratin 19)

MO47022 100 ul
EUR 418.8

Cytokeratin-1 Antibody

39339-100ul 100ul
EUR 468

Cytokeratin-1 Antibody

abx037856-100ug 100 ug
EUR 469.2

Cytokeratin-7 Antibody

48356-100ul 100ul
EUR 399.6

Cytokeratin-7 Antibody

48356-50ul 50ul
EUR 286.8

Cytokeratin-1 Antibody

E301319 200ul
EUR 275
Description: Available in various conjugation types.

Cytokeratin-7 Antibody

E8EM0702 100ul
EUR 225
Description: Available in various conjugation types.

Cytokeratin-7 Antibody

48356 100ul
EUR 429

Cytokeratin-18 Mouse mAb

A0389-100ul 100 ul
EUR 460.8

Cytokeratin-18 Mouse mAb

A0389-200ul 200 ul
EUR 664.8

Cytokeratin-18 Mouse mAb

A0389-20ul 20 ul Ask for price

Cytokeratin-18 Mouse mAb

A0389-50ul 50 ul
EUR 318

Cytokeratin-18 Rabbit pAb

A1022-100ul 100 ul
EUR 369.6

Cytokeratin-18 Rabbit pAb

A1022-200ul 200 ul
EUR 550.8

Cytokeratin-18 Rabbit pAb

A1022-20ul 20 ul
EUR 219.6

Cytokeratin-18 Rabbit pAb

A1022-50ul 50 ul
EUR 267.6

Cytokeratin 19 Protein

20-abx261011
  • EUR 4101.60
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

Cytokeratin 16 Protein

20-abx261285
  • EUR 4101.60
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

Cytokeratin 19 Protein

20-abx261720
  • EUR 4236.00
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

Cytokeratin 20 Protein

20-abx261929
  • EUR 5388.00
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

Cytokeratin 17 Protein

20-abx261959
  • EUR 5388.00
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

Cytokeratin 18 Protein

20-abx261980
  • EUR 5388.00
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

Cytokeratin 20 Protein

20-abx261981
  • EUR 5388.00
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

Cytokeratin 14 Protein

20-abx262029
  • EUR 5388.00
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

Cytokeratin 18 Protein

20-abx262306
  • EUR 393.60
  • EUR 7108.80
  • EUR 276.00
  • 10 ug
  • 1 mg
  • 2 µg

Cytokeratin 14 Protein

20-abx262842
  • EUR 7676.40
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

Cytokeratin 18 protein

30R-AC039 250 ug
EUR 817.2
Description: Purified recombinant Human Cytokeratin 18 protein

Cytokeratin 19 protein

30R-AC040 100 ug
EUR 495.6
Description: Purified recombinant Human Cytokeratin 19 protein

Cytokeratin 8 protein

30R-AC041 100 ug
EUR 501.6
Description: Purified recombinant Human Cytokeratin 8 protein

cytokeratin 20 Peptide

43-166P 0.1 mg
EUR 405.6

cytokeratin 20 Peptide

43-167P 0.1 mg
EUR 405.6

cytokeratin 19 Peptide

43-484P 0.1 mg
EUR 405.6

cytokeratin 19 Peptide

43-491P 0.1 mg
EUR 405.6

Cytokeratin-9 Rabbit pAb

A10119-100ul 100 ul
EUR 369.6

Cytokeratin-9 Rabbit pAb

A10119-200ul 200 ul
EUR 550.8

Cytokeratin-9 Rabbit pAb

A10119-20ul 20 ul
EUR 219.6

Cytokeratin-9 Rabbit pAb

A10119-50ul 50 ul
EUR 267.6

Cytokeratin 23 Antibody

20-abx137380
  • EUR 844.80
  • EUR 393.60
  • EUR 276.00
  • 100 ug
  • 20 ug
  • 5 ug

Cytokeratin 6A Antibody

abx232215-100ug 100 ug
EUR 610.8

Cytokeratin 10 Antibody

abx139680-01mg 0.1 mg
EUR 427.2

Cytokeratin 19 antibody

10-1210 500 ug
EUR 522
Description: Mouse monoclonal Cytokeratin 19 antibody

Cytokeratin 7 antibody

10R-1826 100 ul
EUR 483.6
Description: Mouse monoclonal CK7 antibody

Cytokeratin 8 antibody

10R-2766 100 ul
EUR 444
Description: Mouse monoclonal Cytokeratin 8 antibody

Cytokeratin 19 antibody

10R-6759 1 ml
EUR 482.4
Description: Mouse monoclonal Cytokeratin 19 antibody

Cytokeratin 18 antibody

10R-6766 1 ml
EUR 482.4
Description: Mouse monoclonal Cytokeratin 18 antibody

Cytokeratin 7 antibody

10R-7842 100 ug
EUR 386.4
Description: Mouse monoclonal Cytokeratin 7 antibody

Cytokeratin 18 antibody

10R-7844 100 ug
EUR 366
Description: Mouse monoclonal Cytokeratin 18 antibody

Cytokeratin 4 antibody

10R-7960 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 4 antibody

Cytokeratin 7 antibody

10R-7962 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 7 antibody

Cytokeratin 7 antibody

10R-7963 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 7 antibody

Cytokeratin 8 antibody

10R-7964 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 8 antibody

Cytokeratin 8 antibody

10R-7965 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 8 antibody

Cytokeratin 10 antibody

10R-7966 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 10 antibody

Cytokeratin 10 antibody

10R-7967 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 10 antibody

Cytokeratin 13 antibody

10R-7969 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 13 antibody

Cytokeratin 14 antibody

10R-7970 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 14 antibody

Cytokeratin 17 antibody

10R-7971 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 17 antibody

Cytokeratin 18 antibody

10R-7972 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 18 antibody

Cytokeratin 18 antibody

10R-7973 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 18 antibody

Cytokeratin 18 antibody

10R-7974 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 18 antibody

Cytokeratin 19 antibody

10R-7975 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 19 antibody

Cytokeratin 6 antibody

10R-7978 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 6 antibody

Cytokeratin 16 antibody

10R-7979 100 ug
EUR 457.2
Description: Mouse monoclonal Cytokeratin 16 antibody

Cytokeratin 8 antibody

10R-7980 100 ug
EUR 444
Description: Mouse monoclonal Cytokeratin 8 antibody

Cytokeratin 1 antibody

10R-C155a 200 ug
EUR 705.6
Description: Mouse monoclonal Cytokeratin 1 antibody

Cytokeratin 10 antibody

10R-C157a 100 ug
EUR 766.8
Description: Mouse monoclonal Cytokeratin 10 antibody

Cytokeratin 13 antibody

10R-C158a 50 ug
EUR 534
Description: Mouse monoclonal Cytokeratin 13 antibody

Cytokeratin 14 antibody

10R-C159a 100 ug
EUR 766.8
Description: Mouse monoclonal Cytokeratin 14 antibody

Cytokeratin 17 antibody

10R-C160a 50 ug
EUR 534
Description: Mouse monoclonal Cytokeratin 17 antibody

Cytokeratin 18 antibody

10R-C161a 50 ug
EUR 566.4
Description: Mouse monoclonal Cytokeratin 18 antibody

Cytokeratin 19 antibody

10R-C162a 50 ug
EUR 566.4
Description: Mouse monoclonal Cytokeratin 19 antibody

Cytokeratin 19 antibody

10R-C163a 100 ug
EUR 793.2
Description: Mouse monoclonal Cytokeratin 19 antibody

Cytokeratin 20 antibody

10R-C164a 50 ug
EUR 690
Description: Mouse monoclonal Cytokeratin 20 antibody

Cytokeratin 20 antibody

10R-C164b 50 ug
EUR 748.8
Description: Mouse monoclonal Cytokeratin 20 antibody

Cytokeratin 20 antibody

10R-C164c 50 ug
EUR 1213.2
Description: Mouse monoclonal Cytokeratin 20 antibody

Cytokeratin 2e antibody

10R-C166a 1 mL
EUR 322.8
Description: Mouse monoclonal Cytokeratin 2e antibody

Cytokeratin 4 antibody

10R-C169a 1 ml
EUR 644.4
Description: Mouse monoclonal Cytokeratin 4 antibody

Cytokeratin 6 antibody

10R-C172a 50 ug
EUR 534
Description: Mouse monoclonal Cytokeratin 6 antibody

Cytokeratin 6 antibody

10R-C172b 5 mL
EUR 342
Description: Mouse monoclonal Cytokeratin 6 antibody

Cytokeratin 7 antibody

10R-C174a 50 ug
EUR 534
Description: Mouse monoclonal Cytokeratin 7 antibody

Cytokeratin 8 antibody

10R-C177a 5 mL
EUR 415.2
Description: Mouse monoclonal Cytokeratin 8 antibody

Cytokeratin 8 antibody

10R-C177ax 50 ug
EUR 591.6
Description: Mouse monoclonal Cytokeratin 8 antibody

Cytokeratin 2 antibody

10R-C179a 50 ug
EUR 534
Description: Mouse monoclonal Cytokeratin 2 antibody
The bulk (23/31; 74%) of the most important immunoreactive proteins recognized had been small (≤250 aa), and 20/31 (65%) had been predicted to be secreted effectors. Not like the robust linear antibody epitopes beforehand recognized in TRP and OMP orthologs, there have been contrasting variations within the E. ch. and E. ca. antigenic repertoires, epitopes and ortholog immunoreactivity. This examine reveals quite a few beforehand undefined immunodominant and subdominant antigens, and illustrates the breadth, complexity, and variety of immunoreactive proteins/epitopes in Ehrlichia.
Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Post

A Curious Novel Combination of Nucleophosmin ( NPM1) Gene Mutations Leading to Aberrant Cytoplasmic Dislocation of NPM1 in Acute Myeloid Leukemia (AML)

A Curious Novel Combination of Nucleophosmin ( NPM1) Gene Mutations Leading to Aberrant Cytoplasmic Dislocation of NPM1 in Acute Myeloid Leukemia (AML)A Curious Novel Combination of Nucleophosmin ( NPM1) Gene Mutations Leading to Aberrant Cytoplasmic Dislocation of NPM1 in Acute Myeloid Leukemia (AML)

Nucleophosmin (NPM1) mutations occurring in acute myeloid leukemia (AML) (about 50 up to now recognized) cluster nearly completely in exon 12 and result in frequent modifications on the NPM1 mutants C-terminus, i.e., lack